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A range of glycopolymers comprised of N-acetylgalactosamine were prepared via sequential 
Cu(I)-mediated polymerization and alkyne-azide click (CuAAC). The resulting polymers were 
shown, via multichannel surface plasmon resonance, to interact specifically with human 
Macrophage Galactose Lectin (MGL; CD301) with high affinity (KD = 1.11 µM), but did not bind 
to the mannose/fucose selective human lectin Dendritic Cell-Specific Intercellular adhesion 
molecule-3-Grabbing Non-integrin (DC-SIGN; CD209). The effect of sugar ligand valency on the 
binding (so-called ‘glycoside cluster effect’) of poly(N-acetylgalactosamine) to MGL was 
investigated by varying first the polymer chain length (DP: 100, 64, 40, 23, 12) and then the 
architecture (4- and 8-arm star glycopolymers). The chain length did not have a significant effect 
on the binding to MGL (KD = 0.17 µM – 0.52 µM), however, when compared to a hepatic C-type 
lectin of a similar monosaccharide specificity, the asialoglycoprotein Receptor (ASGPR), the 
binding affinity was more noticeably affected (KD = 0.37 µM – 6.65 µM).  These data suggest that 
known differences in the specific configuration/orientation of the carbohydrate recognition 
domains of MGL and ASGPR are responsible for the differences in binding observed between the 
different polymers of varied chain length and architecture. In the future this model has the potential 
to be employed for the development of tissue selective delivery systems.   
 
INTRODUCTION 
Carbohydrate recognition controls many biological processes and is mediated through 
carbohydrate binding proteins termed lectins.1 One of the most important classes of human lectins 
is the C-type lectin class (CTLs),2–6   and these proteins mediate selective and specific carbohydrate 
recognition and subsequently drive important functions such as endocytosis.7 A number of major 
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C-type lectins are expressed on the surfaces of key immune cells such as macrophages and 
dendritic cells and have been identified as a potential platform for targeted drug delivery and 
synthetic vaccination.8,9 In general all CTLs share high sequence homology and tertiary structure, 
but the carbohydrate specificity can be generalized into two broad groups by tripeptide motifs in 
the Carbohydrate Recognition Domain (CRD) that engages calcium chelation and H-bonding with 
the C3 and C4 hydroxyl groups of the target carbohydrate subcomponent. CTLs such as DC-SIGN 
and Macrophage Mannose Receptor (MR; CD206) that contain the ‘Glu-Pro-Asn’ (EPN) motif in 
the CRD prefer to bind pyranose units with C3/C4 hydroxyls at equatorial/equatorial positions; 
these include mannose, L-fucose, and N-acetylglucosamine (GlcNAc).10 Physiologically, these 
mannose-selective CTLs are generally credited as pathogen pattern recognition receptors.11 In 
contrast to the several members of EPN type CTLs in humans, there are a small set of CTLs with 
the ‘Gln-Pro-Asp’ (QPD) motif in the CRD, and they have preferential binding to galactose-based 
sugars with the C3/C4 pyranosyl hydroxyls at an equatorial/axial position.12 For the two major 
galactose-specific CTLs in the human body, ASGPR and MGL, where the structure and function 
are not fully understood, there have been no direct comparisons between their binding activities to 
synthetic ligands. ASGPR is a hepatic CTL largely expressed on sinusoidal face of hepatocyte 
surfaces, and is responsible for vascular homeostatic regulations13 mediated by recognition of 
terminal galactose/GalNAc residues found on senescent de-sialylated glycan clusters found on 
circulating glycoproteins and platelets.14 In contrast, MGL is an immunological CTL, expressed 
on the surface of macrophages and dendritic cells, implicated in stimulating T-cell signaling.3 
Glycopolymers that interact with biological systems possess considerable potential as novel 
therapeutics and molecular probes. Recent discoveries have led to complex compositions and 
architectures, attracting interest in various fields for numerous applications such as biosensors,15 
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drug delivery components16, cryopreservation, synthetic vaccines9, immunodulators8 and cell 
culture matrices.17 However, the majority of the literature focuses on interactions with plant 
derived lectins such as Concanavalin A (ConA),18 Soybean Agglutinin (SBA),19 Peanut Agglutinin 
(PNA)20 and Helix Pomatia Agglutinin (HPA).21 In the context of human drug delivery and 
therapeutic applications, investigating human immunological C-type lectins such as MR, MGL 
and DC-SIGN is of much higher importance and relevance.   
Historically, the synthesis of well-defined glycopolymers has been a challenge, due to the need for 
complex multistep syntheses. Recently, however, this has been alleviated by the development of 
methods whereby glycopolymers can be synthesized by direct polymerization of glycomonomers. 
For example, Davis et al. exploited chemoenzymatic reactions to synthesize (meth)acrylate22 and 
vinyl-ester23 based glycomonomers which were subsequently polymerized by RAFT using 
dithiocarbonate and xanthate chain transfer agents respectively. Cameron et al. polymerized α-
GalNAc functionalized acrylamide by RAFT as a Tn-antigen mimic and coated gold nanoparticles 
as potential candidates for synthetic, carbohydrate-based anti-cancer vaccines.24 Haddleton and 
coworkers, reported sequence controlled glycopolymers synthesized by single electron transfer 
living radical polymerization (SET-LRP) from a library of glycomonomers.25 Binding studies with 
DC-SIGN26 and its competitive inhibition of the attachment of HIV glycoprotein gp120 was also 
reported. Finally, De Coen and coworkers used acetylated mannose to prepared a mannose-
arcylamide monomer in a single step.27 
Post-polymerization modification of functional polymer scaffolds is a complimentary, efficient 
method for generating libraries of glycopolymers, with well-defined scaffolds accessible from 
commercially available or easily obtainable monomers. Glycidyl (meth)acrylate has been shown 
to be a versatile monomer, yielding scaffolds capable of undergoing thio-epoxy ring opening in 
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the presence of thio-sugars,28 as well as sequential nucleophilic ring opening, by sodium azide, 
and ‘click’ with glycosyl alkynes.29 Activated esters such as pentafluorophenyl and N-
Hydroxysuccinimide (NHS) ester activated polymers are interesting precursor scaffolds, however 
they are often hydrolytically unstable and do not necessary yield quantitative conversions.30 
Bertozzi reported a method involving the attachment of non-functionalized sugar to 
poly(acrylhydrazide) scaffolds via the reducing termini21, however grafting efficiency is reduced 
for N-acetylated carbohydrates. ‘Click’ chemistry is an attractive tool for glycopolymer synthesis 
due to the inherent efficiency and quantitative conversions associated with the reactions. In 
particular Copper(I)-catalyzed Azide Alkyne Cycloaddition (CuAAC) has been employed over the 
past decade to generate glycopolymers.31 Glycosyl azides/alkynes have been efficiently coupled 
to well-defined alkyne/azide-functional scaffolds which can be synthesized by various radical 
polymerization protocols including RAFT,32,33 ATRP34 and cobalt-mediated CCTP.35  
Herein we report the synthesis of N-acetyl galactosamine glycopolymers and their specific / 
differential binding to recombinant human MGL and ASPGR lectins. The difference in binding 
with respect to the degree of polymerization (DPn) and the molecular architecture is also reported. 
EXPERIMENTAL 
Materials and methods  
N-(ethyl)-2-pyridylmethanimine and trimethylsilyl propargyl methacrylate were synthesised 
according to previously published work.36 Copper(I) Bromide (98%, Sigma-Aldrich) was treated 
with acetic acid and ethanol and dried under vacuum prior to use. Amberlite IR120 (Sigma-
Aldrich) was treated with 1M NaOH, de-ionised water and ethanol prior to use. 2-Chloro-1,3-
dimethylimdazolinium chloride (DMC) (>97%, Fluka), N-acetyl-D-glucosamine GlcNAc (>98%, 
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Alfa Aesar), GalNAc (99.6%, Dextra), Triethylamine (TEA) (Fisher scientific, >99%) were used 
as received. All the other reagents and solvents were obtained from Sigma-Aldrich at the highest 
purity available and used without any further purification. Dialysis tubing (1KDa MWCO) was 
supplied by Spectrum Laboratories. Soluble recombinant, tetrameric extracellular domains of DC-
SIGN and DC-SIGNR were prepared as previously described.37 Soluble recombinant Langerin 
trimeric extracellular domain was obtained from Elicityl SA (Grenoble, France). Soluble 
recombinant trimeric MGL extracellular domain and trimeric ASGPR H1 extracellular domain 
proteins were obtained from R&D Systems Inc (Minneapolis, USA). All 1H NMR and 13C NMR 
spectra were recorded on Bruker HD 300 MHz or 400 MHz spectrometers. The chemical shifts 
are reported in ppm with respect to the residual peaks of the deutrated solvents used as internal 
standards and ACDLABS software was used to analyse the data obtained. Infrared absorption 
spectra were recorded on Bruker VECTOR-22 FT-IR spectrometer using a Golden Gate diamond 
attenuated total reflection cell and OPUS software was used to analyse the data. Mass spectra were 
recorded on Bruker Esquire 2000 using ESI. SEC analysis was conducted on Agilent 1260 Infinity 
Multi-Detector GPC Systems in DMF (1.06 gℓ-1 LiBr), calibrated with narrow PMMA standards 
(200 – 4.7 x 105 g.mol-1). The GPC data obtained were analysed using Agilent Technologies 
GPC/SEC software. Melting point was measured using an Optimelt MPA100 system (Stanford 
Research Systems) and the data was analysed with Meltview v.1.108.  
Synthesis 
Representative spectra of the sugar azides and glycopolymers synthesized can be found in the 
supplementary information. 
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Azido sugars. 2-Chloro-1,3-dimethylimdazolinium chloride (4.6 g, 27.1 mmol, 3 eq) was added 
to a mixture of H2O (45 ml), sodium azide (5.9 g, 90.4 mmol, 10 eq), triethylamine (9.2 g, 90.4 
mmol, 10 eq) and D-N-acetylgalactosamine/ D-N-acetylglucosamine (2 g, 9.0 mmol, 1 eq). The 
reaction was left stirring at 0 0C for 1 hour and left to stir over night at ambient room temperature. 
The reaction mixture was concentrated under reduced pressure. Ethanol (100 ml) was added and 
passed through a short column of Amberlite IR-120. The filtrate was concentrated under reduced 
pressure. H2O (10 ml) was added and washed with dichloromethane (3 × 15 ml). The aqueous 
layer was collected and freeze-dried. The resulting yellow solid was redissolved in methanol (10 
ml) and precipitated into dicholoromethane (100 ml) to yield the pure products β-N-
acetylgalactosamine azide (1.2 g, 4.9 mmol, 54 %) and β-N-acetylglucosamine azide (1.0 g, 4.1 
mmol, 45 %) that were spectroscopically equivalent to those previously reported in the literature. 
38 
General procedure for ATRP of trimethylsilyl propargyl methacrylate (linear); N-(ethyl)-2-
pyridylmethanimine (34.2 mg, 255.0 μmol, 2 eq),  ethyl α-bromoisobutyrate (24.8 mg, 127.0 μmol, 
1 eq), trimethylsilyl propargyl methacrylate (2.0 g, 10.2 mmol, 80 eq) and toluene (2 ml) were 
charged to a dry Schlenk tube. The tube was sealed and subjected to seven freeze-pump-thaw 
cycles. The resulting de-gassed mixture was transferred via cannula under nitrogen into a second 
Schlenk tube, previously evacuated and filled with nitrogen, containing Cu(I)Br (18.3 mg, 127.0 
μmol, 1 eq) and a magnetic stirrer. The reaction mixture was stirred at 70°C for 6 hours. The 
conversion was measured by integrating the monomeric OCH2 (4.74 ppm) and emerging 
polymeric OCH2 (4.60 ppm) and comparing it against the vinylic signals (6.16 ppm and 5.58 ppm). 
The polymerisation was stopped at 70% conversion and terminated by diluting reaction mixture 
with 10 ml of toluene before bubbling air for 2 hours. The terminated mixture was passed through 
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a short column of alumina eluting with THF. The solvent was removed under pressure and 
redissolved in THF (10 ml) prior to precipitation in petroleum ether (200 ml). The precipitate was 
separated by centrifugation and decanting the solvent to yield poly(trimethylsilyl propargyl 
methacrylate) (1.1 g) as white solid.  
For investigating the effect of chain length (DPn,th = 10, 20, 40, 60, 100) a benzyl functional 
initiator was employed for more accurate determination of the DPn,NMR using the  aromatic protons 
(7.28-7.38 ppm). The amount of monomer and solvent used was kept constant and the amount of 
initiator used was in accordance to equation 3. The amount of copper and ligand used was adjusted 
with the respect to the initiator with absolute ratio of [Initiator] : [Copper] : [Ligand] / 1 : 1 : 2 for 
each polymerisation.  
𝐷𝑃𝑇ℎ𝑒𝑜𝑟𝑦 =  
[𝑚𝑜𝑛𝑜𝑚𝑒𝑟]
[𝐼𝑛𝑖𝑡𝑖𝑎𝑡𝑜𝑟]
× 𝐶𝑜𝑛𝑣𝑒𝑟𝑠𝑖𝑜𝑛   (eq 3) 
ATRP of trimethylsilyl propargyl methacrylate (4-arm star); General procedure followed 
using a pentaerythritol based tetra-initiator.39 The initiator concentration was calculated according 
to eq 3 taking each bromine group as an effective initiator to calculate effective initiator 
concentration to calculate target DPn per arm. A ratio of [Initiator]eff : [Copper] : Ligand] = 1 : 1 : 
2 ratio used employed.  
ATRP of trimethylsilyl propargyl methacrylate (8-arm star); General procedure followed 
using a lactose based initiator40 under more dilute conditions (25% wt monomer) to limit the 
potential of star-star coupling. The initiator concentration was calculated according to eq 3 taking 
each bromine group as an effective initiator to calculate effective initiator concentration to 
calculate target DPn per arm. A ratio of [Initiator]eff : [Copper] : [Ligand] = 1 : 1 : 2 ratio was 
employed. The reaction was terminated at 49% conversion and the target DPn based of eq 3 was 
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used to estimate the final DP as the lactose core protons were obscured and could not be used to 
determine DPn,NMR.    
 
General procedure for deprotection. Poly(trimethylsilyl propargyl methacrylate) (1.0 g) and 
acetic acid (460.0 mg, 1.5 eq mol/mol with respect to the alkyne-trimethylsilyl groups) were 
dissolved in THF (60 ml) and sealed. The solution was bubbled with nitrogen for 20 minutes and 
then cooled to -20 0C. Solution of 1 M tetrabutylammonium fluoride hydrate (5% wt water) in 
THF (2.3 ml, 1.5 eq mol/mol with respect to the alkyne-trimethylsilyl groups) was added slowly 
into the mixture via syringe. The resulting mixture was stirred at -20 0C for 30 minutes before 
being warmed to ambient temperature for 6 hours. The resulting mixture was passed through a 
short column of silica, using THF as an eluent. The resulting filtrate was concentrated under 
reduced pressure and the polymer was precipitated in water (150 ml). The precipitate was separated 
by centrifugation and decanting the water to yield poly(propargyl methacrylate) (834 mg) as white 
solid. 
General procedure for the synthesis N-acetylated glycopolymers. Poly(propargyl 
methacrylate), sugar azide (1.2 eq mol/mol with respect to the alkyne groups), 2,2’-Bipyridine (0.2 
eq mol/mol with respect to the alkyne groups) and DMSO (5ml) were charged into a dry Schlenk 
tube. The tube was sealed and subjected to seven freeze-pump-thaw cycles. The resulting de-
gassed mixture was transferred via nitrogen under nitrogen into a second Schlenk tube, previously 
evacuated and filled with nitrogen, containing Cu(I)Br (1 eq mol/mol with respect to the alkyne 
groups) and a magnetic stirrer. The reaction mixture was stirred at room temperature for 36 hours. 
The glycopolymer was precipitated into THF. The precipitate was then dissolved in water and 
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treated with cuprisorb until the solution turned colourless. The polymer solution was then dialysed 
using 1KDa MWCO dialysis tubing in de-ionised water for 2 days, changing the water at least 
twice a day. The solution was then freeze-dried over night to yield N-acetylated glycopolymers as 
white solids.  
 
Surface Plasmon Resonance (Amine coupling protein surface immobilisation). Sensorgrams 
were recording using the ProteOn XPR36 instrument (BioRad Laboratories). Lectins were 
immobilised on BioRad ProteOn GLC sensor chips via amine coupling at pH 5.0 using surfaces 
activated with sulfo-N-hydroxysuccinimide. After blocking amine coupling sites with 1 M 
ethanolamine pH 8.0, chip flowcells were equilibrated in running buffer (10 mM HEPES pH 7.4, 
150 mM NaCl, 3 mM CaCl2, 0.01 % NaN3, 0.005 % Tween-20). Glycopolymer analytes were 
prepared in running buffer and flowed over the lectins at 25˚C and a flow rate of 25 µl/min. with 
analyte association times of 300-900 seconds. 
Surface Plasmon Resonance (His-Tag Capture protein surface immobilisation). Lectins were 
immobilised on BioRad ProteOn HTE sensor chips via Histidine tag-capture, using 10 mM Nickel 
Sulfate to activate the surface.  Samples were run straight after lectin immobilisation with running 
buffer (10 mM HEPES pH 7.4, 150 mM NaCl, 3 mM CaCl2, 0.01% NaN3, 0.005% Tween-20) at 
25˚C and a flow rate of 25 µl/min for association time of 300 seconds. Running buffer was flowed 
immediately afterwards for dissociation phase of 375 seconds. The sensor chip was regenerated 
by complete removal of the lectins with 300 mM ethylene glycol-bis(β-aminoethyl ether)-
N,N,N',N'-tetraacetic acid (EGTA), in order to recoat the surface with new lectins.  
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Numerical Fit. The models (eq 1, 2) were fitted numerically using MATLAB, standard errors 
were gained for each parameter by confidence bound of each fit. Response at equilibrium (Req) is 
measured as the average response over the last 20 seconds of the association phase (response as 




  (eq 1) 
To obtain dissociation rate, a decay equation (eq 2) was fitted to the dissociation phase (buffer 
flow). The Response unit at the start of the dissociation phase was taken as the initial response unit 
(R0):  
Rt =  R0exp (−kofft)  (eq 2) 




 (eq 4) 
RESULTS AND DISCUSSION 
Synthesis of the N-acetylated glycopolymers.  
Reversible deactivation radical polymerization (RDRP) is a popular method for the preparation of 
glycopolymers. This study was initiated by the synthesis and polymerization of a protected alkyne-
functional monomer, trimethylsilyl propargyl methacrylate (TMS-PgMA) in accordance with 
previous reports.34 Atom Transfer Radical Polymerization (ATRP) of TMS-PgMA was employed 
using ethyl α-bromoisobutyrate (EBiB) as initiator and Cu(I)Br/N-(ethyl)-2-pyridylmethanimine 
(NEPI) as catalyst in toluene (50 wt%) at 70 0C ([TMS-PgMA] : [EBiB] : [Cu(I)Br] : [NEPI] = 
[80] : [1] : [1] : [2]). The polymerization was stopped before reaching full conversion to reduce 
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the occurrence of bimolecular termination (ρ = 68%, DPn,NMR = 69, Mn,NMR = 13600 g mol-1, Ɖ = 
1.30, Table 1, entry 1). Conversions were determined by monitoring the disappearance of vinylic 
protons at δ = 6.11 – 5.56 ppm, relative to residual CHCl3 (7.26 ppm) and the degree of 
polymerisation (DPn) and number average molecular weight (Mn,NMR) were determined by 
comparing the methylene signal present in the initiator end group (δ = 4.09 ppm) with a methylene 
signal in the polymer side chain at purification (δ = 4.60 ppm, Figure S1). The trimethylsilyl 
protecting groups were cleaved using tetra-N-butylammonium fluoride (TBAF)  and acetic acid to 
afford an alkyne-functional polymer scaffold (Mn,NMR = 8700 g mol
-1, Ɖ = 1.40, Table 1, entry 2) 
as indicated by the disappearance of the TMS signal in 1H NMR (δ = 0.2 ppm) which coincided 
with the appearance of a signal for the alkyne proton (δ = 2.5 ppm, Figure S2). Anomerically pure 
β-glycosyl azides of N-acetyl galactosamine (GalNAc) and N-acetyl glucosamine (GlcNAc), 
prepared via the one-step procedure of S. Shoda et al.41–43 (Figure S3-6), were then ‘clicked’ onto 
the pendant alkyne groups according to a literature procedure28 using Cu(I)Br and bypyridine to 
furnish GalNAc (GP1, Table 1, entry 3) and GlcNAc (GP2, Table 1, entry 4) functional 
glycopolymers from a single polymer scaffold. The success of the cycloaddition reaction was 
confirmed by FT-IR, with the disappearance of the alkyne peak (ʋ(C-H): 3286 cm-1 and ʋ(C≡C): 
2129 cm-1, Figure S7) and 1H NMR with the appearance of a signal corresponding to the triazole 
hydrogen (δ = 8.30 ppm, Figure S8-9). 
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Scheme 1. Synthesis of PGalNAc prepared by sequential Cu(I)-mediated polymerization and 
azide-alkyne click; i) CuBr, N-(ethyl)-2-pyridylmethanimine, toluene, 70 °C; ii) TBAF, AcOH, 
THF, -20 °C;  iii) CuBr, bipy, sugar azide, DMSO, RT. 
Table 1. Molecular weight data for the synthesized polymer scaffold and glycopolymers 








1 P(TMSPgMA) 10900a 13600b 15400 1.30 
2 P(PgMA) 6900d 8700d 9700 1.40 
3 GP1 20300d 25600d 22600 1.25 
4 GP2 20300d 25600d 24300 1.26 
aDetermined by MWmonomer x conversion x [M]0/[I]0 + MWinitiator. 
bAs calculated by NMR of the 
α-end group to determine DPn. cDetermined by size-exclusion chromatography (with DMF as the 
eluent) using conventional calibration obtained with poly(methyl methacrylate) standards (Figure 
S10). dMn based DPn = 69 for the P(TMSPgMA) scaffold.  
Investigating binding interactions of MGL with N-acetylated glycopolymers (GP1-GP2).  
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MGL has only been reported to be expressed in subtypes of macrophages and dendritic cells as a 
scavenger receptor that facilitates antigen presentation of nonself-antigens.44 MGL expression is 
implicated in cancer progression and binds to GalNAc based tumour-associated carbohydrate (Tn-
antigen) on the mucin molecule MUC145 expressed by malignant cells.46 Binding to MGL is 
reported to drive Th2-mediated responses via the MHC class II processing and presentation 
pathway,47 as opposed to tumourcidal Th1 responses.48 Although the engagement of MGL by 
ligands per se may not direct a specific response, it may influence and impact responses via co-
engagement of other receptors.49 Therefore, from a bottom-up approach it was necessary to 
investigate whether our polymers could also interact with MGL as well as closely related CTLs.  
The association and binding of glycopolymers to the target lectins was investigated using multi-
channel Surface Plasmon Resonance (SPR). 
Figure 1. SPR sensorgrams for the binding of glycopolymers GP1 (A-D) and GP2 (E-H) with 
lectins MGL, DC-SIGN, DC-SIGNR and Langerin. GP1 / GP2 were flowed at 0.25 µLs-1 for 375 
seconds with varying concentration range to determine association. Buffer was flowed between t 
= 375 and 900 seconds to establish the dissociation phase. 
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Soluble, recombinant MGL extracellular portion (CRD domain and coiled-coil neck) was 
immobilized on the chip surface through EDC-NHS mediated amine coupling with carboxylic acid 
coated alginate on the SPR sensor chip.50 Extracellular portions of the closely related 
immunological CTLs: DC-SIGN, DC-SIGNR and Langerin were also immobilised onto chips for 
parallel investigations to assess their interactions with the N-acetylated glycopolymers (GP1 and 
GP2). The glycopolymers (range: 1.25 – 40 µM in serial 2:1 dilution) were flowed over, in parallel, 
across each lectin-bearing channel, followed immediately by buffer alone (see supporting info for 
full details). The sensorgrams (Figure 1) show clear concentration dependent association of 
PGalNAc GP1 to MGL with slow dissociation. GP1 did not bind to the other lectins (DC-SIGN, 
DC-SIGNR and Langerin) inferring high selectivity for MGL. In contrast, PGlcNAc, GP2 was 
observed to bind to DC-SIGN and other related EPN-type lectins, but did not bind to MGL (Figure 
1, Table 2). The extent of binding can be quantified using the SPR software via a two state model 
for glycopolymer-lectin interactions.26,50 From this fitting two KD values are obtained. For the 
purpose of this investigation a simple Langmuir-type isotherm fitting of each interaction was 
employed as a parsimonious model to quantify the glycopolymer-lectin interaction as a single 
dissociation equilibrium constant (KD, eq 1). Individual rate constants were obtained separately; 
dissociate rate (koff) from the dissociation phase (eq 2) and an apparent association rate, as the 
quotient of KD and koff.  
Table 2. Binding parameters of glycopolymers GP1 and GP2 with human lectins obtained from 
SPR, eq1 and eq2. 
Pol lectin kon,app 
(x 102 M-1s-1) 
koff 
b   





GP1 MGL 2.62 2.88 1106 
 DC-SIGN - - - 
 DC-DIGNR - - - 
 Langerin - - - 
GP2 MGL - - - 
 DC-SIGN 2.49 3.59 1442 
 DC-SIGNR 1.12 3.24 2907 
 Langerin 8.58 4.95 577 
a As determined by : 𝑅𝑒𝑞 =
𝑅𝑚𝑎𝑥[𝑝𝑜𝑙]
𝐾𝐷+[𝑃𝑜𝑙]
         (eq 1) 
b As determined by:  𝑅𝑡 =  𝑅0exp (−𝑘𝑜𝑓𝑓𝑡)                (eq 2) 
Investigating the effect of chain length and polymer architecture on binding affinity.  
Typically, plant and human derived lectins exist as multimeric assemblies and as a result individual 
CTL-sugar interactions are weak. Multimeric, or multivalent sugar ligands often confer much 
stronger binding than monomeric and short oligomeric equivalents. This phenomenon is widely 
referred to as the ‘glycoside cluster effect’.51 One of the advantages of using RDRP protocols is 
the ability to control polymer chain length and architecture. Thus, it is possible to manipulate 
ligand multivalency by varying the number and orientation of pendant sugar groups present within 
target glycopolymers. Furthermore, the possibility of forming well-defined block copolymers 
provides access to higher-ordered structures such as micelles, vesicles and nano-gels wherein the 
density of sugar ligands present can in intricately controlled by the monomer feed. To this end, De 
Coen and coworkers have investigated the potential of mannosylated nano-gels to target MR 
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expressed on dendritic cells and found that increased particle size and ligand (mannose) density 
resulted in enhanced receptor binding and internalization.27 
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Figure 2. PGalNAc library synthesized by ATRP to investigate the effect of ligand valency on 
lectin binding.  
To investigate the effect of polymer chain length and architecture on binding to MGL, a library of 
linear PGalNAc polymers (GP3-GP7) of varying chain length (DPn 12-100, Table S1, Figure S11) 
were prepared by ATRP employing a benzyl initiator34 which enabled more accurate analysis of 
the number average molecular weight by 1H NMR by comparing the distinctive benzyl protons 
(7.28-7.38 ppm) against OCH2-R (4.59 ppm) of the polymer side chain (Figure S12). Likewise, 
alternative architectures were prepared using 4-arm (pentaerythritol-based) and 8-arm (lactose-
based) initiators (Figure 2). Employing ATRP, the copper and ligand concentration was adjusted 
to account for each initiating group. The DPn of the 4-arm star PGalNAc (GP8, Mn,Th = 45600 
g.mol-1, Ɖ = 1.30, Table S1, Figure S11) was determined as 30 per arm according to the monomer 
conversion (ρ  ̴ 60 %) from an [M]:[I] ratio of 200 employed during P(TMSPgMA) scaffold 
synthesis. The core methylene protons (4.33 ppm) from the initiator were obscured which 
prohibited accurate determination of DPn by 
1H NMR. Likewise the DPn of the 8-arm star 
PGalNAc (GP9, Mn,Th = 34900 g.mol
-1, Ɖ = 1.22, Table S1, Figure S11) was also determined by 
monomer conversion as the core lactose ring protons (3.84 -5.86 ppm) could not be reliably 
integrated by 1H NMR. Polymerization from the 8-arm initiator was carried out under more diluted 
conditions (25 wt%) with [M]:[I] ratio of 360 and was terminated at lower monomer conversion 
(ρ ̴ 49 %) to reduce the occurrence of star-star coupling,52,53 furnishing an 8-arm star PGalNAc 
with DPn of 22 per arm. 
During the initial study (GP1-2), all lectins were covalently bound to SPR chips via established 
amine coupling chemistry.26 Removal of bound polymers from covalently immobilized lectins, 
usually via chelation chemistry (EGTA)54 or simple acid treatment (pH 3 glycine buffer),26 limits 
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the number of sequential experiments due to denaturation of the bound proteins.  For a more 
reliable comparison of the PGalNAc library (GP3-9), fresh lectin was used for each SPR 
experiment to ensure the binding was not influenced by the previous experiment. This was carried 
out using Bio-Rad Laboratories ProteOnTM HTE Sensor chip, which contains tris-nitrilotriacetic 
acid, reported to have subnanomolar affinity towards His-tagged molecules.55 Thus, His-tagged 
MGL was reversibly immobilized to a nickel sulfate activated SPR chip prior to analysis. Polymer-
bound lectins were then rapidly removed using chelating agent EGTA before immobilization of a 
fresh batch of His-tagged MGL between each subsequent experiment. 
The binding of PGalNAc to MGL was largely unchanged as a function of the polymer valency 
(Figure 3). Although increasing the linear chain length, from DPn = 12 to DPn = 100 (GP3-7) was 
found to lower the overall KD of the polymer, the differences were not significant (517 – 169 nM, 
Figure 3, Table 3). The architecture of the PGalNAc polymers also had little effect on the binding 
to MGL with the 4-arm star (GP8) and 8-arm star PGalNAc (GP9), exhibiting comparable binding 
to the linear analogues (157 nM and 240 nM respectively, Figure 3, Table 3). A similar observation 
was previously reported by Stenzel and coworkers, whereby the binding of glucose-containing 4-
arm star glycopolymers to ConA, did not show a significant effect on binding compared to linear 
analogues.18 As the association rate directly reflects the dissociation constant by our method, a 
similar trend was observed whereby PGalNAc appeared to bind marginally faster as a function of 
increasing valency (410 – 1870 M-1.s-1, Table 3), whereas only minor changes in the dissociation 




Figure 3. Binding constants of glycopolymers GP3-GP9 with MGL determined from SPR (Figure 
S20). 
To date, the structure of MGL has not been fully elucidated, but has been reported to share 
similarities with DC-SIGN and Mannose binding protein (MBP) where the CRDs are relatively 
distant and face away from one another. Such an orientation might be expected to be ideal for 
cross-linking via multivalent ligands.56 Indeed, one of the immunological functions of MGL has 
been attributed to cross-linking of CD45 expressed on the surface of activated T cells, modulating 
their behaviour.57 Structurally, chemical cross-linking experiments have shown that MGL exists 
as a homotrimer.56 Trimerization occurs in the neck domain and is independent of the CRD, with 
the junction between the two domains being protease sensitive. This indicates that the CRD 
consists of three discrete, distally orientated sugar binding sites that are potentially dynamic and 
capable of adjusting to compliment the glycan clusters presented to the lectin surface, similar to 
MBP.56  Therefore it is proposed that the three binding sites interact independently with the 
PGalNAc polymers employed during this investigation. On a molecular level, this translates to the 
polymers not having to traverse the multiple binding sites of a single MGL trimer to enhance 
binding. 
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Relative binding of PGalNAc with ASGPR and MGL.  
In comparison to MGL, ASGPR was discovered much earlier58 and the structure and function has 
been more extensively explored.59  Native human ASGPR consists of two different chains, H1 and 
H2, forming a hetero-oligomer.60 Despite this, to date there are currently no crystal structures of 
the complete extracellular domain of the native H1/H2 heterooligomer, but the arrangement and 
orientation of the CRD is well investigated and optimal ASGPR ligands reported in the literature 
are selected based on the spatial arrangement of Gal residues within the native tri/tetra-antennary 
N-glycans.61 The recombinant ASGPR used during this investigation (CRD and neck domain of 
H1 subunit), is a self-assembled homotrimer,62 the structure of which closely resembles the native 
hetero-oligomer lectin, in which the binding sites are in close proximity,54 presenting an interface 
more suitable for clustered glycosides, typically at the termini of a single, branched 
oligosaccharide. From previous literature pertaining to monosaccharide selectivity,63 it was 
hypothesised that APSGR would exhibit similar binding selectivity to MGL. Having demonstrated 
binding of PGalNAc (GP1, 1.62 µM), and a lack of binding of PGlcNAc (GP2) to ASGPR (Figure 
4A,B), the effect of chain length and architecture was again investigated. The overall binding of 
PGalNAc (GP3-GP9) to ASGPR was found to be lower than MGL, particularly for short polymer 
chain lengths (GP3-5, Table 3). However, a more pronounced effect on binding with changing the 
valency of PGalNAc was observed.   
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Figure 4. SPR sensorgrams for the binding of glycopolymers GP1 (A) and GP2 (B) with ASGPR. 
GP1 / GP2 were flowed at 0.25 µLs-1 for 300 seconds with varying concentration range to 
determine association. Buffer was flowed between t = 300 and 700 seconds to establish the 
dissociation phase. Binding constants of glycopolymers GP3-GP9 with APSGR determined from 
SPR (Figure S21)  
Table 3. The effect of ligand valency on the binding of PGalNAc glycopolymers to MGL and 
ASGPR 




Ɖc KD     
(nM) 
kon,app                
(x 102 M-1.s-1) 
koff                 
(x 10 -4 s-1) 
KD     
(nM) 
kon,app                
(x 102 M-1.s-1) 
koff                    
(x 10 -4 s-1) 
GP3 12 4700 1.15 517 4.10 2.12 6653 0.35 2.33 
GP4 23 8800 1.34 390 4.27 1.66 6652 0.39 2.58 
GP5 40 15100 1.30 388 8.90 3.45 5535 0.71 3.94 
GP6 64 24000 1.13 211 9.17 1.94 712 3.56 2.57 
GP7 100 37300 1.21 169 15.70 2.64 372 12.00 4.47 
GP8 30 / armb 45600b 1.30 157 18.70 2.94 341 10.20 3.47 
GP9 22 / armb 68000b 1.22 240 13.50 3.26 560 8.23 4.61 
aDetermined by 1H NMR via integration of the benzyl protons (7.28-7.38 ppm) of the chain end 
against OCH2-R (4.59 ppm) of the polymer. 
bApproximated from data obtained for the polymer 
scaffold (Table S1).  cDetermined by size-exclusion chromatography (with DMF as the eluent) 
using conventional calibration obtained with Poly(methyl methacrylate) standards (Figure S11). 
dDetermined SPR whereby GP3-9 were flowed at 0.25 µLs-1 for 375 seconds to afford association 
before buffer was flowed (t = 375-900 seconds) to establish the dissociation phase (Figure S20 -
S21). 
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At shorter chain lengths, the binding of linear PGalNAc (GP3-5) to ASGPR was comparable 
(GP3-5, 6.7 – 5.5 μM). When the chain length was increased further, the dissociation constant 
decreased much more significantly than previously observed for MGL (GP6-7, 712 – 372 nM). 
Similarly to MGL, no significant effect was observed upon changing the polymer architecture 
(GP8-9, 560 - 341 nM). Molecularly, this indicates that low molecular weight PGalNAc (GP3-5) 
share similar binding modes, as indicated by minimal changes in the KD. ASGPR has been reported 
to bind markedly weaker to monovalent GalNAc ligands and as such ASGPR ligands are often 
based on a tri/tetra-antennary design to compliment the more rigid, proximal binding sites of the 
multivalent ASGPR oligomer.64,65 When the chain length of the PGalNAc ligand is increased 
beyond DPn = 64 the binding to ASGPR is markedly enhanced as a result of the ‘glycoside cluster 
effect’ whereby the multivalent PGalNAc ligands are capable of binding to multiple binding sites 
of ASGPR, thus overcoming the individually weak interactions. 
The differential binding of MGL and ASGPR was further exemplified using a GalNAc-BSA 
conjugate, where single GalNAc moieties are randomly exposed through conjugation to surface 
serine and threonine residues. Only binding to MGL, with its distally orientated, flexible CRD, 
was observed, and no binding was observed to the more rigid, proximal binding sites of ASGPR 
which requires more closely configured sugar ligands (Figure 5). The PGalNAc polymers 
synthesized during this investigation were predicted to be long enough to span the proximal 
binding sites of the ASGPR which are separated by approximately 15-25 Å.66 With this in mind, 
the shortest PGalNAc (DPn = 12.5, GP3) should be sufficiently long enough to bind to at least two 
of the binding sites based on a perfectly linear conformation, whilst GP5 (DPn = 40) should be 
sufficiently long enough to bind to all three binding sites of the trimer. However, the 
glycopolymers do not exist as ideal linear chains in solution, and as a result changes in the KD were 
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only observed at longer chain lengths (GP6-GP7, DPn = 64, 100). Thus, the ‘glycoside cluster 
effect’ was apparent at longer chain lengths as the conformation of the polymer in solution 
promotes binding at multiple sites of the lectin CRD. Furthermore, beyond a critical chain length, 
secondary interactions that result in cross-linking between ASGPR oligomers are possible which 
could contribute to the stronger binding interactions observed. 
Figure 5. SPR sensorgrams for the binding of BSA-GalNAc conjugate to MGL (A) and ASGPR 
(B). BSA-GalNAc conjugate was flowed at 0.25 µLs-1 for 300 seconds with varying concentration 
range to determine association. Buffer was flowed between t = 300 and 700 seconds to establish 
the dissociation phase. 
Bertozzi et al. previously described an analogous system in plant lectins; Helix Pomatia Agglutinin 
(HPA) and Soybean Agglutinin (SBA), where HPA (proximal binding sites) was found to interact 
strongly in a valence independent manner and SBA (distant binding sites) to reversibly ‘bind and 
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slide’ leading weaker interactions.19 Conversely, this investigation has demonstrated that binding 
to ASGPR, with proximal binding sites, occurs in a valence dependent manner, whereas MGL, 
with its flexible, distal binding sites binds independent of valence with affinity attributed a 
preference for multi-molecular lectin binding via cross-linking through the glycopolymer scaffold. 
These contrasting conclusions serve to highlight the complexity of lectin/glycopolymer 
interactions which are strongly dependent upon the nature of lectin(s) and polymers under 
investigation. 
CONCLUSION 
A library of PGalNAc glycopolymers have been used for the first time to perform binding studies 
with human CTL’s MGL and ASGPR. A polyalkyne scaffold prepared by Cu(I)-mediated radical 
polymerization was functionalized with azido-GalNAc and azido-GlcNAc respectively and the 
binding and selectivity of the resulting polymers was assessed against target lectins MGL and 
ASGPR as well as related CTLs DC-SIGN, DC-SIGNR and Langerin using SPR. PGalNAc was 
found to specifically bind to MGL and shows little affinity for related CTLs. Conversely, PGlcNAc 
exhibits little affinity for MGL but binds to the related CTLs with varying affinity. Increasing the 
ligand valency by increasing the DPn of the PGalNAc resulted in only a small increase in affinity, 
which remained unchanged as a function of polymer architecture. This is attributed to the distal 
orientation and flexibility of the carbohydrate binding domain of MGL. One the other hand 
ASGPR, which is known to have a more proximal orientated binding domain, exhibits comparable 
selectivity of PGalNAc and conforms in-part, to the ‘glycoside cluster effect.’ For example, 
increasing the GalNAc valency by increasing the DPn of the PGalNAc exhibited a marked increase 
in affinity. The specific binding thresholds reported are opportunistic for further exploitation, with 
potential implications in tissue-selective drug delivery. For example, it is known that GalNAc 
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based ligands can successfully target the liver via ASGPR in vivo without being obstructed by the 
immune system.67 Therefore, ASGPR represents a promising entry for liver-specific drug and gene 
delivery using PGalNAc glycopolymers. Alternatively, selectively targeting the immune system 
using GalNAc based systems represents a greater challenge due to competitive uptake by the 
hepatic system. It is hoped that the differential binding observed between MGL and ASGPR in 
this study can be exploited to systemically target macrophages and DCs via MGL without off-
target uptake to liver via ASGPR. Due to their pivotal role in tumour immunology, macrophages 
and DCs could provide a set of clinically valuable targets.68 Thus targeting tumour environments 
via the carbohydrate binding properties of MGL could provide a favourable and selective 
therapeutic delivery strategy, due to its higher expression in sites of solid tumours.69 
ASSOCIATED CONTENT 
This material is available free of charge via the Internet at http://pubs.acs.org. This includes 









† Nanjing University of Science and Technology, School of Environmental and Biological 
Engineering, Nanjing University, Luohan Alley, Xuanwu Qu, Nanjing Shi, Jiangsu Sheng, 
China, 210094. 
ACKNOWLEDGMENT 
The authors gratefully acknowledge financial support from Engineering and Physical Sciences 
Research Council (EPSRC) under grant EP/F500378/1 through the Molecular Organisation and 
Assembly in Cells Doctoral Training Centre (MOAC-DTC). The authors also wish to acknowledge 
the facilities and personnel (K.K., D.M.H., T.P.D., S.P., P.W.) enabled by the Monash-Warwick 
Alliance. This work was carried out in conjunction with the Australian Research Council (ARC) 
Centre of Excellence in Convergent Bio-NanoScience and Technology (CE140100036). A.S.M. 
holds a Medical Research Award from the General Charity of the City of Coventry. R.W. is funded 
by Syngenta. K.K. gratefully acknowledges the award of a NHMRC-ARC Dementia Research 
Development Fellowship (APP1109945). T.P.D. gratefully acknowledges support from the ARC 
in the form of an Australian Laureate Fellowship. S.P. acknowledges a Royal Society Wolfson 
Merit Award (WM130055). PW thanks the Leverhulme Trust for the award of an Early Career 
Fellowship (ECF/2015-075).  
REFERENCES 
(1)  Zanetta, J.-P.; Kuchler, S.; Maschke, S.; Thomas, D.; Dufourcq, P.; Vincendon, G. 
Histochem. J. 1992, 24, 791–804. 
(2)  Glavey, S. V; Huynh, D.; Reagan, M. R.; Manier, S.; Moschetta, M.; Kawano, Y.; Roccaro, 
A. M.; Ghobrial, I. M.; Joshi, L.; Dwyer, M. E. O. Blood Rev. 2015, 29, 269–279. 
(3)  Kooyk, Y. Van; Ilarregui, J. M.; Vliet, S. J. Van. Immunobiology 2015, 220, 185–192. 
 28 
(4)  Liu, F.; Patterson, R. J.; Wang, J. L. Biochim. Biophys. Acta 2002, 1572, 263–273. 
(5)  Urban, Š.; Anderluh, M. Cell. Signal. 2010, 22, 1397–1405. 
(6)  Zachara, N. E.; Hart, G. W. Biochim. Biophys. Acta 2006, 1761, 599–617. 
(7)  Spiess, M. Biochemistry 1990, 29, 10009–10018. 
(8)  Ohta, M.; Ishida, A.; Toda, M.; Akita, K.; Inoue, M.; Yamashita, K. Biochem. Biophys. Res. 
Commun. 2010, 402, 663–669. 
(9)  Sunasee, R.; Narain, R. Macromol. Biosci. 2013, 13, 9–27. 
(10)  Lee, R. T.; Hsu, T. L.; Huang, S. K.; Hsieh, S. L.; Wong, C. H.; Lee, Y. C. Glycobiology 
2011, 21, 512–520. 
(11)  Cambi, A.; Koopman, M.; Figdor, C. G. Cell. Microbiol. 2005, 7, 481–488. 
(12)  Kolatkar, A. R.; Weis, W. I. J. Biol. Chem. 1996, 271, 6679–6685. 
(13)  Grozovsky, R.; Begonja, A. J.; Liu, K.; Visner, G.; Hartwig, J. H.; Falet, H.; Hoffmeister, 
K. M. Nat. Med. 2014, 21, 47–54. 
(14)  Hoffmeister, K. M. J. Thromb. Haemost. 2011, 9, 35–43. 
(15)  Richards, S.-J.; Otten, L.; Gibson, M. I. J. Mater. Chem. B 2016, 4, 3046–3053. 
(16)  Song, E.; Manganiello, M. J.; Chow, Y.; Ghosn, B.; Convertine, A. J.; Stayton, P. S.; 
Schnapp, L. M.; Ratner, D. M. Biomaterials 2012, 33, 6889–6897. 
(17)  Hayward, A. S.; Eissa, A. M.; Maltman, D. J.; Sano, N.; Przyborski, S. A.; Cameron, N. R. 
Biomacromolecules 2013, 14, 4271–4277. 
(18)  Chen, Y.; Chen, G.; Stenzel, M. H. Macromolecules 2010, 43, 8109–8114. 
(19)  Godula, K.; Bertozzi, C. R. J. Am. Chem. Soc. 2012, 134, 15732–15742. 
(20)  Lu, J.; Zhang, W.; Richards, S.-J.; Gibson, M. I.; Chen, G. Polym. Chem. 2014, 5, 2326–
 29 
2332. 
(21)  Godula, K.; Bertozzi, C. R. J. Am. Chem. Soc. 2010, 132, 9963–9965. 
(22)  Albertin, L.; Stenzel, M. H.; Barner-Kowollik, C.; Foster, L. J. R.; Davis, T. P. 
Macromolecules 2005, 38, 9075–9084. 
(23)  Albertin, L.; Kohlert, C.; Stenzel, M.; Foster, J. R.; Davis, T. P. Biomacromolecules 2004, 
5, 255–260. 
(24)  Parry, A. L.; Clemson, N. a; Ellis, J.; Bernhard, S. S. R.; Davis, B. G.; Cameron, N. R. J. 
Am. Chem. Soc. 2013, 135, 9362–9365. 
(25)  Zhang, Q.; Wilson, P.; Anastasaki, A.; McHale, R.; Haddleton, D. M. ACS Macro Lett. 
2014, 3, 491–495. 
(26)  Zhang, Q.; Collins, J.; Anastasaki, A.; Wallis, R.; Mitchell, D. A.; Becer, C. R.; Haddleton, 
D. M. Angew. Chemie Int. ed 2013, 52, 4435–4439. 
(27)  De Coen, R.; Vanparijs, N.; Risseeuw, M. D. P.; Lybaert, L.; Louage, B.; De Koker, S.; 
Kumar, V.; Grooten, J.; Taylor, L.; Ayres, N.; Van Calenbergh, S.; Nuhn, L.; De Geest, B. 
G. Biomacromolecules 2016, 17, 2479–2488. 
(28)  Zhang, Q.; Anastasaki, A.; Li, G.-Z.; Haddleton, A. J.; Wilson, P.; Haddleton, D. M. Polym. 
Chem. 2014, 5, 3876. 
(29)  Basuki, J. S.; Esser, L.; Duong, H. T. T.; Zhang, Q.; Wilson, P.; Whittaker, M. R.; 
Haddleton, D. M.; Boyer, C.; Davis, T. P. Chem. Sci. 2014, 5, 715. 
(30)  Das, A.; Theato, P. Chem. Rev. 2016, 116, 1434–1495. 
(31)  Slavin, S.; Burns, J.; Haddleton, D. M.; Becer, C. R. Eur. Polym. J. 2011, 47, 435–446. 
(32)  Krieg, A.; Becer, C. R.; Hoogenboom, R.; Schubert, U. S. Macromol. Symp. 2009, 275–
276, 73–81. 
(33)  Semsarilar, M.; Ladmiral, V.; Perrier, S. Macromolecules 2010, 43, 1438–1443. 
 30 
(34)  Ladmiral, V.; Mantovani, G.; Clarkson, G. J.; Cauet, S.; Irwin, J. L.; Haddleton, D. M.; 
Jean, F.; Valery, F. J. Am. Chem. Soc. 2006, 19, 4823–4830. 
(35)  Nurmi, L.; Lindqvist, J.; Randev, R.; Haddleton, D. M. Chem. Commun. 2009, 2727–2729. 
(36)  Haddleton, D. M.; Crossman, M. C.; Dana, B. H.; Duncalf, D. J.; Heming, A. M.; Kukulj, 
D.; Shooter, A. J. Macromolecules 1999, 32, 2110–2119. 
(37)  Mitchell, D. A.; Fadden, A. J.; Drickamer, K. J. Biol. Chem. 2001, 276, 28939–28945. 
(38)  Hong, S. Y.; Tobias, G.; Oualid, F. El; Errey, J. C.; Doores, K. J.; Kirkland, A. I.; Nellist, 
P. D.; Green, M. L. H.; Davis, B. G.; Ballesteros, B.; El Oualid, F.; Errey, J. C.; Doores, K. 
J.; Kirkland, A. I.; Nellist, P. D.; Green, M. L. H.; Davis, B. G.; Oualid, F. El; Errey, J. C.; 
Katie, J. J. Am. Chem. Soc. 2007, 129, 10966–10967. 
(39)  Jones, M.-C.; Ranger, M.; Leroux, J.-C. Bioconjug. Chem. 2003, 14, 774–781. 
(40)  Limer, A. J.; Rullay, A. K.; San, V.; Peinado, C.; Keely, S.; Fitzpatrick, E.; Carrington, S. 
D.; Brayden, D.; Haddleton, D. M. React. Funct. Polym. 2006, 66, 51–64. 
(41)  Vinson, N.; Gou, Y.; Becer, C. R.; Haddleton, D. M.; Gibson, M. I. Polym. Chem. 2011, 2, 
107. 
(42)  Tanaka, T.; Ishitani, H.; Miura, Y.; Oishi, K.; Takahashi, T.; Suzuki, T.; Shoda, S. I.; 
Kimura, Y. ACS Macro Lett. 2014, 3, 1074–1078. 
(43)  Shoda, S.-I.; Tanaka, T.; Nagai, H.; Noguchi, M.; Kobayashi, A. Chem. Commun. 2009, 
3378–3379. 
(44)  Napoletano, C.; Zizzari, I. G.; Rughetti, A.; Rahimi, H.; Irimura, T.; Clausen, H.; Wandall, 
H. H.; Belleudi, F.; Bellati, F.; Pierelli, L.; Frati, L.; Nuti, M. Eur. J. Immunol. 2012, 42, 
936–945. 
(45)  Saeland, E.; Van Vliet, S. J.; Bäckström, M.; Van Den Berg, V. C. M.; Geijtenbeek, T. B. 
H.; Meijer, G. a.; Van Kooyk, Y. Cancer Immunol. Immunother. 2007, 56, 1225–1236. 
 31 
(46)  Hollingsworth, M. a.; Swanson, B. J. Nat. Rev. Cancer 2004, 4, 45–60. 
(47)  Napoletano, C.; Rughetti, A.; Agervig Tarp, M. P.; Coleman, J.; Bennett, E. P.; Picco, G.; 
Sale, P.; Denda-Nagai, K.; Irimura, T.; Mandel, U.; Clausen, H.; Frati, L.; Taylor-
Papadimitriou, J.; Burchell, J.; Nuti, M. Cancer Res. 2007, 67, 8358–8367. 
(48)  Carlos, C. a.; Dong, H. F.; Howard, O. M. Z.; Oppenheim, J. J.; Hanisch, F.-G.; Finn, O. J. 
J. Immunol. 2005, 175, 1628–1635. 
(49)  Zizzari, I. G.; Napoletano, C.; Battisti, F.; Rahimi, H.; Caponnetto, S.; Pierelli, L.; Nuti, M.; 
Rughetti, A. J. Immunol. Res. 2015, 2015, 8 pages. 
(50)  Becer, C. R.; Gibson, M. I.; Geng, J.; Ilyas, R.; Wallis, R.; Mitchell, D. a.; Haddleton, D. 
M. J. Am. Chem. Soc. 2010, 132, 15130–15132. 
(51)  Lundquist, J. J.; Toone, E. J. Chem. Rev. 2002, 102, 555–578. 
(52)  Barner-Kowollik, C.; Davis, T. P.; Stenzel, M. H. Aust. J. Chem. 2006, 59, 719–727. 
(53)  Whitfield, R.; Anastasaki, A.; Truong, N. P.; Wilson, P.; Kempe, K.; Burns, J. A.; Davis, 
T. P.; Haddleton, D. M. Macromolecules 2016, 49, 8914–8924. 
(54)  Venkatraman Girija, U.; Furze, C. M.; Gingras, A. R.; Yoshizaki, T.; Ohtani, K.; Marshall, 
J. E.; Wallis,  a K.; Schwaeble, W. J.; El-Mezgueldi, M.; Mitchell, D. a; Moody, P. C. E.; 
Wakamiya, N.; Wallis, R. BMC Biol. 2015, 13, 27. 
(55)  Huang, Z.; Hwang, P.; Watson, D. S.; Cao, L.; Szoka, F. C. Bioconjug. Chem. 2009, 20, 
1667–1672. 
(56)  Jégouzo, S. A.; Quintero-Martínez, A.; Ouyang, X.; Dos Santos, Á.; Taylor, M. E.; 
Drickamer, K. Glycobiology 2013, 23, 853–864. 
(57)  van Vliet, S. J.; Gringhuis, S. I.; Geijtenbeek, T. B. H.; van Kooyk, Y. Nat. Immunol. 2006, 
7, 1200–1208. 
(58)  Ashwell, G.; Morell, A. G. Adv. Enzym. Relat. Areas Mol. Biol. 1974, 41, 99–128. 
 32 
(59)  Weigel, P. H.; Yik, J. H. N. Biochim. Biophys. Acta 2002, 1572, 341–363. 
(60)  Bischoff, J.; Lodish, H. F. J. Biol. Chem. 1987, 262, 11825–11832. 
(61)  Khorev, O.; Stokmaier, D.; Schwardt, O.; Cutting, B.; Ernst, B. Bioorganic Med. Chem. 
2008, 16, 5216–5231. 
(62)  Geffen, I.; Wessels, H. P.; Roth, J.; Shia, M. a; Spiess, M. Embo J. 1989, 8, 2855–2861. 
(63)  van Vliet, S. J.; Liempt, E. van; Saeland, E.; Aarnoudse, C. A.; Appelmelk, B.; Irimura, T.; 
Geijtenbeek, T. B. H.; Blixt, O.; Alvarez, R.; Die, I. van; Kooyk, Y. Van. Int. Immunol. 
2005, 17, 661–669. 
(64)  Biessen, E. A. L.; Beuting, D. M.; Roelen, H. C. P. F.; Boom, J. H. Van; Berkelf, T. J. C. 
Van. J. Med. Chem. 1995, 38, 1538–1546. 
(65)  Prakash, T. P.; Yu, J.; Migawa, M. T.; Kinberger, G. A.; Wan, W. B.; Østergaard, M. E.; 
Carty, R. L.; Vasquez, G.; Low, A.; Chappell, A.; Schmidt, K.; Aghajan, M.; Crosby, J.; 
Murray, H. M.; Booten, S. L.; Hsiao, J.; Soriano, A.; Machemer, T.; Cauntay, P.; Burel, S. 
A.; Murray, S. F.; Gaus, H.; Graham, M. J.; Swayze, E. E.; Seth, P. P. J. Med. Chem. 2016, 
59, 2718–2733. 
(66)  Meier, M.; Bider, M. D.; Malashkevich, V. N.; Spiess, M.; Burkhard, P. J. Mol. Biol. 2000, 
300, 857–865. 
(67)  Dhande, Y. K.; Wagh, B. S.; Hall, B. C.; Sprouse, D.; Hackett, P. B.; Reineke, T. M. 
Biomacromolecules 2016, Articles ASAP. 
(68)  Solinas, G.; Schiarea, S.; Liguori, M.; Fabbri, M.; Pesce, S.; Zammataro, L.; Pasqualini, F.; 
Nebuloni, M.; Chiabrando, C.; Mantovani,  a.; Allavena, P. J. Immunol. 2010, 185, 642–
652. 
(69)  Allavena, P.; Chieppa, M.; Bianchi, G.; Solinas, G.; Fabbri, M.; Laskarin, G.; Mantovani, 
A. Clin. Dev. Immunol. 2010, 2010, 547179. 
 33 
  
 
